Ironwood Pharmaceuticals is in the black for the first time thanks to its complex spinoff of pre-commercial drug development programs.
McKesson and Walgreens are strong, healthy companies, despite recent downturns in their stock prices, a CEO in the investment field says.
AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.
Each year dozens of shareholder proposals seek to quash potential conflicts of interest by calling for an independent chair. But they hardly ever pass.
Ironwood’s Tom Graney tries to focus investors on the firm’s pipeline rather than its revenue.
The acquisition of Zeltiq Aesthetics' system for using cooling to eliminate fat cells gives Allergan access to the growing body-contouring market.
The SEC says the drug maker failed to timely inform investors about its merger talks with Salix and Actavis.
The Botox maker will pay up to $1.7 billion for Tobira, the developer of an experimental treatment for a nonalcoholic fatty liver condition.
The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.
The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.
